Hims & Hers Health’s (HIMS) “Neutral” Rating Reiterated at Piper Sandler

Piper Sandler reissued their neutral rating on shares of Hims & Hers Health (NYSE:HIMS) in a research note released on Tuesday morning,Benzinga reports. The firm currently has a $21.00 price objective on the stock, up from their prior price objective of $18.00.

Several other equities analysts have also commented on the stock. Deutsche Bank Aktiengesellschaft upped their price target on shares of Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Truist Financial lifted their target price on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 18th. Bank of America upped their target price on Hims & Hers Health from $23.00 to $25.00 and gave the company a “buy” rating in a report on Monday, October 21st. Canaccord Genuity Group boosted their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Imperial Capital cut shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $21.00.

Hims & Hers Health Stock Down 2.5 %

Shares of NYSE HIMS traded down $0.59 during trading on Tuesday, hitting $23.03. 9,613,026 shares of the company traded hands, compared to its average volume of 8,641,587. Hims & Hers Health has a 1 year low of $6.58 and a 1 year high of $25.74. The firm has a market capitalization of $4.95 billion, a P/E ratio of 53.68 and a beta of 1.06. The company has a 50-day moving average price of $18.57 and a 200-day moving average price of $18.33.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 11.67%. The firm’s revenue was up 77.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.04) earnings per share. Research analysts predict that Hims & Hers Health will post 0.22 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, Director Christiane Pendarvis sold 7,000 shares of the firm’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total value of $106,050.00. Following the sale, the director now owns 23,917 shares of the company’s stock, valued at $362,342.55. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Patrick Harrison Carroll sold 15,000 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $22.07, for a total transaction of $331,050.00. Following the completion of the transaction, the insider now directly owns 196,941 shares of the company’s stock, valued at approximately $4,346,487.87. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christiane Pendarvis sold 7,000 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total transaction of $106,050.00. Following the transaction, the director now owns 23,917 shares in the company, valued at $362,342.55. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 854,547 shares of company stock valued at $15,987,230 in the last 90 days. 17.71% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC grew its position in Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares during the period. Quest Partners LLC raised its holdings in Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after buying an additional 3,507 shares during the period. CWM LLC grew its stake in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after acquiring an additional 1,054 shares in the last quarter. Van ECK Associates Corp acquired a new position in Hims & Hers Health in the second quarter valued at $111,000. Finally, Amalgamated Bank raised its holdings in shares of Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after buying an additional 2,354 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.